Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.
西妥昔单抗和纳武利尤单抗治疗复发/转移性头颈癌的 II 期临床试验的长期生存率和分子生物标志物评估。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-2201
Chaudhary Ritu, Moorhead Graydon, Park Robin, Li Jiannong, Schell Michael J, Song Xiaofei, Tan AikChoon, Slebos Robbert J C, Biernacki Maria I, Freeman Samuel S, Thatikonda Sowjanya, Meshkovska Yeva, Hernandez-Prera Juan, Kirtane Kedar, Guevara-Patino Jose A, Amelio Antonio L, Rocco James W, Danysh Brian P, Bonomi Marcelo, Saba Nabil F, Haradhvala Nicholas J, Getz Gad, Chung Christine H